JAK/STAT signaling
JAK/STAT signaling inhibitors are compounds that disrupt the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway, which is involved in cytokine signaling, cell growth, and immune response. These inhibitors are important tools in studying the regulation of this pathway and its role in various diseases, including cancers, immune disorders, and inflammatory conditions. JAK/STAT inhibitors are also being developed as targeted therapies for these diseases. At CymitQuimica, we provide a wide selection of high-quality JAK/STAT signaling inhibitors to support your research in molecular biology, oncology, and immunology.
Subcategories of "JAK/STAT signaling"
Found 361 products of "JAK/STAT signaling"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
NVP-BSK805
CAS:NVP-BSK805 (BSK 805) is an ATP-competitive JAK2 inhibitor.Formula:C27H28F2N6OPurity:98%Color and Shape:SolidMolecular weight:490.55TLC1566-0618
CAS:TLC1566-0618 shows antitumor activity and targets stat.Formula:C20H15NO3S3Purity:98%Color and Shape:SolidMolecular weight:413.53Golotimod TFA
CAS:Golotimod TFA (SCV 07 TFA) is a dipeptide exhibiting immunomodulatory and antibacterial activity, alleviates radiation-induced oral mucositis.Formula:C18H20F3N3O7Purity:98%Color and Shape:SoildMolecular weight:447.36(3S,4S)-Tofacitinib
CAS:(3S,4S)-Tofacitinib, a less active enantiomer of tofacitinib, is a Janus kinases inhibitor.Formula:C16H20N6OPurity:98%Color and Shape:SolidMolecular weight:312.37JAK3-IN-12
CAS:JAK3-IN-12 (compound 15k) is a potent inhibitor of JAK3 (IC50: 9.5 nM) and can be used in the study of rheumatoid arthritis.Formula:C19H19N5O4SColor and Shape:SolidMolecular weight:413.45K00135
CAS:K00135 (IMIDAZOPYRIDAZIN 1) is a selective inhibitor of Pim kinases and can be used in studies about gastric cancer and antileukemic therapeutics.Formula:C18H18N4OPurity:98.16%Color and Shape:SolidMolecular weight:306.36JAK-IN-11
CAS:JAK-IN-11 (R-348) is a potent and selective inhibitor of JAK, has the potential for the skin disorders treatment.Formula:C23H22FN5O4SPurity:99.75%Color and Shape:SolidMolecular weight:483.52CX-6258
CAS:CX-6258 is an orally valid Pim 1/2/3 kinase(IC50=5 nM/25 nM/16 nM) inhibitor. It has good biological activity and kinase specificity.Formula:C26H24ClN3O3Purity:97.46%Color and Shape:SolidMolecular weight:461.94Ref: TM-T1834
1mg34.00€5mg75.00€10mg101.00€25mg197.00€50mg295.00€100mg447.00€200mg623.00€1mL*10mM (DMSO)77.00€JAK-IN-20
CAS:JAK-IN-20: potent oral JAK1,2,3 inhibitor with IC50s 7, 5, 14 nM respectively, good pharmacokinetics, anti-inflammatory in vivo.Formula:C28H30FN7O2Color and Shape:SolidMolecular weight:515.58Niclosamide monohydrate
CAS:Niclosamide Monohydrate is used for the treatment of most tapeworm infections by inhibiting DNA replication.Formula:C13H10Cl2N2O5Purity:98%Color and Shape:SolidMolecular weight:345.14Peficitinib hydrochloride
CAS:Peficitinib HCl (ASP015K) is an oral JAK inhibitor with IC50s: JAK1 (3.9 nM), JAK2 (5.0 nM), JAK3 (0.7 nM), Tyk2 (4.8 nM).Formula:C18H23ClN4O2Color and Shape:SolidMolecular weight:362.86TK4b
CAS:TK4b, a JAK inhibitor, targets leukemia/lymphoid diseases, with IC50s: 18.42 nM (JAK3) & 19.40 nM (JAK2).Formula:C21H22N2O2Color and Shape:SolidMolecular weight:334.41TK4g
CAS:TK4g, a potent JAK inhibitor, has IC50s of 12.61 nM (JAK2) & 15.80 nM (JAK3); promising for lymphoid diseases & leukemia research.Formula:C19H19N3O4SColor and Shape:SolidMolecular weight:385.44JAK-2/3-IN-2
CAS:JAK-2/3-IN-2 (Compound 3h) is a potent JAK2 & JAK3 inhibitor with IC50s of 23.85 nM (JAK2) & 18.9 nM (JAK3).Formula:C19H19ClN2OSColor and Shape:SolidMolecular weight:358.89XZH-5
CAS:XZH-5 is an inhibitor of STAT3.Formula:C22H25F6N5O4Purity:98%Color and Shape:SolidMolecular weight:537.46JAK-IN-14
CAS:JAK-IN-14 (compound 16) is a specific JAK1 inhibitor. It prevents JAK1 phosphorylation by binding to the active site of JAK in immune, inflammation and cancer.Formula:C19H15FN4OPurity:98.27%Color and Shape:SolidMolecular weight:334.35Ref: TM-T9764
1mg81.00€5mg170.00€10mg268.00€25mg555.00€50mg888.00€100mg1,414.00€200mg1,882.00€1mL*10mM (DMSO)178.00€TyK2-IN-2
CAS:TyK2-IN-2 is a selective inhibitor of TYK2 (IC50s: 7 nM, 0.1 μM, and 0.05 μM for TYK2 JH2, IL-23, and IFNα).Formula:C16H18N6OPurity:98%Color and Shape:SolidMolecular weight:310.35JAK-IN-18
CAS:"JAK-IN-18: potent JAK inhibitor for eye, skin, respiratory disease research (WO2018204238A1, comp 1)."Formula:C27H28F2N6O3Color and Shape:SolidMolecular weight:522.55Tyk2-IN-5
CAS:Tyk2-IN-5 is a selective and orally active inhibitor of Tyk2 JH2 (Ki: 0.086 nM for Tyk2 JH2; IC50: 25 nM for IFNα).Formula:C21H19FN8O2Purity:98%Color and Shape:SolidMolecular weight:434.43Tyk2-IN-7
CAS:Tyk2-IN-7 is an inhibitor of TYK2 JH2, binds to the TYK2 JH2 domain (IC50: 0.00053 μM; Ki.app: 0.00007 μM).Formula:C18H15D3N6O3SPurity:98%Color and Shape:SolidMolecular weight:401.46MS-1020
CAS:MS-1020 inhibits JAK3/STAT3, blocks active JAK3, suppresses JAK3/STAT5 signaling, and targets STAT3 in certain cells.Formula:C21H18N2O3Purity:98%Color and Shape:SolidMolecular weight:346.381,2,3,4,5,6-Hexabromocyclohexane
CAS:Inhibits JAK2 autophosphorylation; non-cytotoxic at 100μM; 1μM reduces activity by 50%, 50μM nearly abolishes it.Formula:C6H6Br6Purity:98%Color and Shape:SolidMolecular weight:557.54OICR-0547
CAS:OICR-0547 is an inactive derivative of OICR-9429 and is commonly used as a negative control for OICR-9429.Formula:C28H29F3N4O4Purity:98%Color and Shape:SolidMolecular weight:542.55JAK3-IN-9
CAS:JAK3-IN-9, potent JAK3 inhibitor, IC50 of 1.7 nM, highly selective, low toxicity, orally bioavailable, shows anti-arthritis activity.Formula:C17H23N5O4SColor and Shape:SolidMolecular weight:393.46EP009
CAS:EP009, a novel, selective, and orally active inhibitor of JAK3, induces therapeutic response in T-cell malignancies.Formula:C14H24O2Color and Shape:SolidMolecular weight:224.34INCB16562
CAS:INCB16562: oral JAK1/2 inhibitor, halts IL-6/STAT3 in myeloma cells, boosts drug efficacy, stunts myeloma in mice.Formula:C19H11Cl2N5Color and Shape:SolidMolecular weight:380.23BP-5-087
CAS:BP-5-087 is a STAT3 inhibitor, combining with BCR-ABL1 inhibition to overcome kinase-independent resistance in chronic myeloid leukemia.Formula:C36H30F8N2O6SColor and Shape:SolidMolecular weight:770.69Galiellalactone
CAS:inhibits IL-6-mediated JAK/STAT signal transductionFormula:C11H14O3Purity:98%Color and Shape:SolidMolecular weight:194.23CP-690550A
CAS:Cp-690550a is a novel JAK3 inhibitor, which is used to treat rheumatoid arthritis, graft rejection, psoriasis, and other immune-mediated diseases.Formula:C15H21N5O2Color and Shape:SolidMolecular weight:303.36GDC-4379
CAS:GDC-4379 is a JAK1 inhibitor that can be used to study asthma.Formula:C21H18ClF2N7O3Color and Shape:SolidMolecular weight:489.86Peficitinib hydrobromide
CAS:Peficitinib hydrobromide is used in the treatment of Psoriasis and Rheumatoid Arthritis.Formula:C18H23BrN4O2Color and Shape:SolidMolecular weight:407.312Povorcitinib
CAS:Povorcitinib is a highly potent and selective JAK1 inhibitor with significant potential for the investigation of cutaneous lupus erythematosus (CLE) and Lichen planus (LP).Formula:C23H22F5N7OColor and Shape:SolidMolecular weight:507.469(2R,5S)-Ritlecitinib
CAS:(2R,5S)-Ritlecitinib ((2R,5S)-PF-06651600) is a potent and selective inhibitor of JAK3 with IC 50 of 144.8 nM[1].Formula:C15H19N5OColor and Shape:SolidMolecular weight:285.34YM-341619
CAS:YM-341619 (AS1617612), potent STAT6 inhibitor; IC50: 0.70 nM; hinders IL-4-induced Th2 in mice; may aid allergic disease research.Formula:C22H21F3N6O2Color and Shape:SolidMolecular weight:458.44TUL01101
CAS:TUL01101, a selective oral JAK1 inhibitor (IC50: 3 nM), also targets JAK2, JAK3, TYK2; for rheumatoid arthritis research.Formula:C22H25F2N5O2Color and Shape:SolidMolecular weight:429.46Stafia-1-dipivaloyloxymethyl ester
CAS:Stafia-1 suppresses pSTAT5a in a dose-dependent manner (0-200 μM) without affecting pSTAT5b.Formula:C37H48FO13PColor and Shape:SolidMolecular weight:750.74MM-206
CAS:MM-206, a cell-permeable, non-cytotoxic naphthalene sulfonamide compound, it effectively inhibits STAT3 DNA-binding activity.Formula:C22H12F5NO3S2Color and Shape:SolidMolecular weight:497.46MC0704
MC0704: STAT3 inhibitor, IC50=2.13μM, promotes apoptosis & cell arrest, anti-breast cancer, for mTNBC research.Formula:C29H21BrN4O2Color and Shape:SolidMolecular weight:537.41STAT3-IN-15
STAT3-IN-15: Potent, oral STAT3 inhibitor for IPF, blocks STAT3 phosphorylation, cell migration, and EMT.Formula:C20H17F3N2O3SColor and Shape:SolidMolecular weight:422.42Thi-DPPY
CAS:Thi-DPPY: Potent JAK3/BTK inhibitor (IC50: 1.38/62.4 nM), anti-proliferative, anti-inflammatory, potential in IPF research.Formula:C28H28ClN5O4SColor and Shape:SolidMolecular weight:566.07HJC0149
CAS:HJC0149 is a potent orally bioavailable signal transducer and activator of transcription 3 inhibitor.Formula:C15H10ClNO4SColor and Shape:SolidMolecular weight:335.76TYK2-IN-11
CAS:TYK2-IN-11 (5B) selectively inhibits TYK2 (IC50: 0.016 nM) and JAK1 (IC50: 0.31 nM), aiding autoimmune and inflammatory disease research.Formula:C18H17N5O3SColor and Shape:SolidMolecular weight:383.42SYK/JAK-IN-1
CAS:SYK/JAK-IN-1 is a dual SYK/JAK inhibitor with IC50 values of less than 5 nM for both SYK and JAK2.Formula:C24H26N8O3Color and Shape:SolidMolecular weight:474.52PF-00956980
CAS:PF-00956980: reversible JAK inhibitor, IC50: JAK1 (2.2μM), JAK2 (23.1μM), JAK3 (59.9μM), for lung/skin inflammation research.Formula:C18H26N6OColor and Shape:SolidMolecular weight:342.44LLL12
CAS:LLL12 inhibits STAT3 phosphorylation, boosting Cisplatin and Paclitaxel effects against ovarian cancer cell activities.Formula:C14H9NO5SColor and Shape:SolidMolecular weight:303.29JAK-IN-10
CAS:JAK-IN-10 is a JAK inhibitor. JAK-IN-10 can be used for the research of dry eye disorders.Formula:C20H18FN5O3SPurity:99.53%Color and Shape:SolidMolecular weight:427.45Ref: TM-T13571
1mg82.00€5mg167.00€10mg246.00€25mg405.00€50mg572.00€100mg772.00€500mg1,539.00€1mL*10mM (DMSO)178.00€JAK3-IN-1
CAS:JAK3-IN-1 is an orally active, selective and potent JAK3 inhibitor for the study of immune system disorders.Formula:C26H30ClN7O2Color and Shape:SolidMolecular weight:508.02JMS-053
CAS:JMS-053 is a phosphatase DUSP3 inhibitor that inhibits CDC25B and prevents VEGF from disrupting the microvascular endothelial barrier.Formula:C13H8N2O2SPurity:≥98.0%Color and Shape:SolidMolecular weight:256.28TP-5801
CAS:TP-5801 is an orally active non-receptor tyrosine kinase (TNK1) inhibitor with an IC50 value of 1.40 nM and antitumor effects.Formula:C24H31BrN8OColor and Shape:SolidMolecular weight:527.46AC430
CAS:AC430, a specific JAK2 inhibitor for cancer and autoimmune therapy, excels in preclinical trials with low doses. Developed by Ambit.Formula:C19H16FN5OColor and Shape:SolidMolecular weight:349.36CAY10784
CAS:CAY10784(STAT3-IN-17) is a STAT3 inhibitor with antiproliferative and antitumor activities. CAY10784 showed antibacterial activity against Clostridium difficileFormula:C11H6F3N3O3SPurity:99.74%Color and Shape:SolidMolecular weight:317.24JAK-IN-21
CAS:JAK-IN-21 is a selective and potent JAK inhibitor that inhibits JAK1, JAK2, J2V617F and TYK2 with IC50 values of 1.73, 2.04, 109 and 62.9 nM, respectively.Formula:C19H16N8OPurity:99.87%Color and Shape:SolidMolecular weight:372.38inS3-54-A26
CAS:inS3-54-A26 is an inhibitor of the DNA-binding domain of STAT3. inS3-54-A26 suppresses tumor growth, metastasis and the gene expression of STAT3.Formula:C25H19ClN2O2Purity:99.57%Color and Shape:SolidMolecular weight:414.88Ref: TM-T27613
1mg109.00€2mg163.00€5mg241.00€10mg355.00€25mg532.00€50mg745.00€100mg1,018.00€500mgTo inquireJAK-IN-30
CAS:JAK-IN-30 (compound 31) is a water-soluble inhibitor of Janus kinases (JAKs), demonstrating inhibitory potency with half-maximal inhibitory concentration (IC50Formula:C19H26N8SPurity:98%Color and Shape:SolidMolecular weight:398.53JAK-IN-28
CAS:JAK-IN-28 (Compound 111) is a Janus kinase (JAK) inhibitor potentially applicable in the research of cancer and inflammatory diseases [1].Formula:C20H18ClN7OPurity:98%Color and Shape:SolidMolecular weight:407.86AZD-1897
CAS:AZD-1897 is a highly efficient ATP-competitive pan-PIM inhibitor with anti-cancer and anti-leukemia activity, used in multiple myeloma research.Formula:C18H23N3O3SPurity:99.49%Color and Shape:SolidMolecular weight:361.46M-110
CAS:M-110 selectively targets PIM kinases, best at PIM-3 (IC50=47nM), and inhibits prostate cancer cell growth (IC50=0.6-0.9μM).Formula:C22H28ClN5O3Purity:99.55%Color and Shape:SolidMolecular weight:445.94JAK1-IN-4
CAS:JAK1-IN-4 selectively blocks JAK1 (IC50 = 85 nM) over JAK2/JAK3 and halts STAT3 phosphorylation in NCI-H 1975 cells (IC50 = 227 nM).Formula:C26H32FN9O2Purity:98%Color and Shape:SolidMolecular weight:521.59JAK3/BTK-IN-2
CAS:JAK3/ BTk-in-2 is a potent JAK3/BTK inhibitor.
Formula:C25H32N8O2Purity:99.64% - 99.87%Color and Shape:SolidMolecular weight:476.57Lorpucitinib
CAS:Lorpucitinib (JNJ-64251330) is a JAK kinase inhibitor used in the study of inflammatory and gastrointestinal diseases.Formula:C22H28N6O2Purity:99.72%Color and Shape:SolidMolecular weight:408.5JAK3i
CAS:JAK3i selectively inhibits JAK3 kinase, targeting the second, vital wave of STAT5 phosphorylation for T cell growth.Formula:C18H15FN4O3Purity:98.61% - 99.81%Color and Shape:SolidMolecular weight:354.34Jaspamycin
CAS:Jaspamycin (7-CN-7-C-Ino) does not bind with purified human PKARIα.Formula:C12H12N4O5Color and Shape:SolidMolecular weight:292.25PIM-1 Inhibitor 2
CAS:PIM-1 Inhibitor 2 (PIM1-IN-2) is a potent Pim-1 inhibitor with potential anti-cancer activity, used in cancer research.Formula:C17H11ClN4OPurity:98.81%Color and Shape:SolidMolecular weight:322.75SD-1029
CAS:SD-1029 is a JAK2 inhibitor and a novel Stat3 activation inhibitor that inhibits Stat3 phosphorylation and JAK-STAT signaling.Formula:C25H32Br2Cl2N2O3Color and Shape:SolidMolecular weight:639.25JAK1-IN-8
CAS:JAK1-IN-8, a specific inhibitor of Janus kinase 1 (JAK1, IC50<500 nM).
Formula:C22H23FN4O3SPurity:98.4%Color and Shape:SolidMolecular weight:442.51Izencitinib
CAS:Izencitinib (JNJ-8398) is a JAK inhibitor with potential anti-inflammatory activity for the study of ulcerative colitis and Crohn;s disease.Formula:C22H26N8Purity:99.82%Color and Shape:SolidMolecular weight:402.50Ref: TM-T35898
1mg84.00€5mg177.00€10mg281.00€25mg567.00€50mg888.00€100mg1,431.00€200mg1,963.00€1mL*10mM (DMSO)195.00€JAK-STAT-IN-1
CAS:JAK-STAT-IN-1 is a specific JAK-STAT inhibitor indicated for the study of autoimmune diseases.Formula:C21H21N5O2Purity:99.59%Color and Shape:SolidMolecular weight:375.42STS-E412
CAS:STS-E412 is a tissue-protective and selective EPOR/CD131 receptor activator for the study of neurological disorders.Formula:C15H15ClN4O2Purity:99.01%Color and Shape:SolidMolecular weight:318.76Butyzamide
CAS:Butyzamide: oral Mpl activator, non-peptide, antagonizes TPO receptors, boosts hMpl, Ba/F3 cells, and enhances platelets in mice.Formula:C29H32Cl2N2O5SPurity:99.39% - 99.83%Color and Shape:SoildMolecular weight:591.55Ref: TM-T67894
1mg149.00€5mg253.00€10mg371.00€25mg573.00€50mg862.00€100mg1,305.00€200mg1,755.00€1mL*10mM (DMSO)329.00€NT219
CAS:NT219 is a dual inhibitor of insulin receptor substrate 1/2 (IRS1/2) and STAT3 that enhances the aggregation of misfolded prion proteins NT219 Effects.Formula:C16H14BrNO5SPurity:98.06% - 99.72%Color and Shape:SolidMolecular weight:412.26TCJL37
CAS:TCJL37: potent, selective TYK2 inhibitor (K i 1.6 nM), oral, for IBD research.Formula:C17H11ClF2N4O2Color and Shape:SolidMolecular weight:376.74PM-43I
CAS:PM-43I is a potent inhibitor of both STAT5- and STAT6-dependent allergic airway disease in mice.Formula:C38H50F2N3O10PColor and Shape:SolidMolecular weight:777.79Lepzacitinib
CAS:Lepzacitinib is a selective, inflammatory, small molecule JAK1/3(Janus kinase) inhibitor primarily used for the treatment of atopic dermatitis.Formula:C18H21N5O3Purity:99.85%Color and Shape:SolidMolecular weight:355.39Ref: TM-T78207
1mg50.00€5mg104.00€10mg167.00€25mg340.00€50mg505.00€100mg712.00€200mg1,009.00€1mL*10mM (DMSO)114.00€JAK2-IN-4
CAS:JAK2-IN-4 is a selective JAK2/JAK3 inhibitor, with IC50 values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively.Formula:C23H27N5O4SPurity:98%Color and Shape:SolidMolecular weight:469.56JAK-IN-31
CAS:JAK-IN-31 (Example 75), a JAK inhibitor, demonstrates IC50 values of ≤0.01 µM for JAK1, ≤0.01 µM for JAK2, 0.01-0.1 µM for JAK3, and ≤0.01 µM for Tyk2,Formula:C21H19N7O2S2Purity:98%Color and Shape:SolidMolecular weight:465.55TCS 21311
CAS:TCS 21311 (NIBR3049) selectively inhibits JAK3 (IC50: 8 nM) and PKCα/θ & GSK3β; >100x selective over JAK1, JAK2, TYK2.Formula:C27H25F3N4O4Purity:99.39% - ≥98%Color and Shape:SolidMolecular weight:526.51JAK-IN-24
CAS:JAK-IN-24: JAK inhibitor, IC50: 0.534 nM (4 μM ATP), 24 nM (1mM ATP), STAT5 phosphorylation IC50: 86.171 nM.Formula:C20H25N5O2Color and Shape:SolidMolecular weight:367.44Upadacitinib tartrate
CAS:Upadacitinib: potent, selective JAK1 inhibitor, 74x preferential to JAK2, effective in rat arthritis.Formula:C21H33F3N6O11Purity:98%Color and Shape:SolidMolecular weight:602.521JAK-IN-26
CAS:JAK-IN-26 (compound 2) is an orally active inhibitor of the Janus kinase (JAK) enzyme with favorable pharmacokinetic properties, exhibiting potency inFormula:C22H24N6O3Purity:98%Color and Shape:SolidMolecular weight:420.46STAT3-IN-14
CAS:STAT3-IN-14 is a STAT3 inhibitor and has STAT3 phosphorylation inhibitory activity. STAT3-IN-14 can directly bind to the hinge region of STAT3 .Formula:C14H10O5Color and Shape:SolidMolecular weight:258.23PIM-IN-2
CAS:PIM-IN-2 (Pim-2) is a potent inhibitor of Pim kinases, demonstrating an inhibition concentration half-maximal (IC50) value of 25 nM .Formula:C19H22N4O2Purity:98%Color and Shape:SolidMolecular weight:338.4STAT6-IN-1
CAS:STAT6-IN-1: STAT6 inhibitor, IC50=0.028 µM, targets SH2 domain, for allergy and cancer research.Formula:C33H37IN3O7PColor and Shape:SolidMolecular weight:745.54JAK-IN-1
CAS:JAK-IN-1 shows improved selectivity for JAK3 over JAK1. JAK-IN-1 is a JAK1/2/3 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively.Formula:C20H24N6O2Purity:98%Color and Shape:SolidMolecular weight:380.44Pim-1 kinase inhibitor 5
CAS:Pim-1 kinase inhibitor 5 (Compound 4c), with an IC50 of 0.61 μM, exhibits cytotoxicity against various cancer cell lines, including HepG2, MCF-7, PC3, and HCT-Formula:C22H13Cl2N3OPurity:98%Color and Shape:SolidMolecular weight:406.26PIM1-IN-1
CAS:PIM1-IN-1 inhibits PIM1/3 with IC50s: PIM1 (7 nM), PIM2 (5530 nM), PIM3 (70 nM); it has anti-cancer properties.Formula:C25H30N8O2Purity:98.59%Color and Shape:SolidMolecular weight:474.56GNE-955
CAS:GNE-955 is a potent and orally active inhibitor of pan Pim kinase (Kis: 0.018, 0.11, 0.08 nM for Pim1, Pim2, Pim3, respectively).Formula:C22H24N8OPurity:98%Color and Shape:SolidMolecular weight:416.48Tubulin/JAK2-IN-1
CAS:Tubulin/JAK2-IN-1 (compound 7g) serves as a potent dual inhibitor targeting both Janus kinase 2 (JAK2) and microtubules, demonstrating significantFormula:C22H20N6O3Color and Shape:SolidMolecular weight:416.43inS3-54A18
CAS:inS3-54A18 is an effective inhibitor of STAT3. inS3-54A18 has anticancer effects.Formula:C23H16ClNO2Purity:99.68%Color and Shape:SolidMolecular weight:373.83Ref: TM-T15582
2mg39.00€5mg62.00€10mg87.00€25mg152.00€50mg215.00€100mg304.00€200mg427.00€1mL*10mM (DMSO)67.00€JAK-IN-17
"JAK-IN-17: Potent JAK inhibitor for studying ocular, skin, and respiratory diseases."Formula:C33H38F2N6O8Color and Shape:SolidMolecular weight:684.69ABBV-712
CAS:ABBV-712 is a selective Tyrosine Kinase 2 (TYK2) inhibitor, demonstrating an IC50 value of 0.195 μM, and is implicated in the regulation of autoimmune diseasesFormula:C24H28N4O5Purity:98%Color and Shape:SolidMolecular weight:452.5Tyk2-IN-9
CAS:Tyk2-IN-9: selective Tyk-2 inhibitor, IC50 of 0.076 nM (TYK2-JH2), 1.8 nM (JAK1-JH2), for inflammation/autoimmune research.Formula:C20H17N9Purity:98%Color and Shape:SolidMolecular weight:383.41STAT3 degrader-2
CAS:STAT3 Degrader-2 is a PROTAC-based compound that effectively reduces the total STAT3 protein levels, and is utilized in the research of cancer and variousFormula:C59H62N9O13PPurity:98%Color and Shape:SolidMolecular weight:1136.15FD1024
CAS:FD1024 is a potent PIM inhibitor, displaying inhibitory concentrations (IC50s) of 1.96 nM, 38.9 nM, and 4.17 nM for PIM1, PIM2, and PIM3, respectively.Formula:C21H20F2N4O2SPurity:98%Color and Shape:SolidMolecular weight:430.47STAT3-IN-20
CAS:STAT3-IN-20 (Compound 40), with an IC50 of 0.65 μM, is a selective inhibitor targeting the SH2 domain of STAT3, thereby impeding its phosphorylation, nuclearFormula:C30H27F4N7SPurity:98%Color and Shape:SolidMolecular weight:593.64Antitumor agent-73
CAS:Antitumor Agent-73, derived from Diosgenin, blocks STAT3 and activates Pdia3, showing strong cancer cell line efficacy.Formula:C50H82BrO4PPurity:98%Color and Shape:SolidMolecular weight:858.06Ginsenoside Rk1
CAS:Ginsenoside Rk1 is a component created by processing the ginseng plant at high temperatures.Formula:C42H70O12Purity:98.46% - 99.13%Color and Shape:SolidMolecular weight:767.00JAK kinase-IN-1
CAS:JAK kinase-IN-1 (Example 1) functions as a potent inhibitor targeting the JAK family, which includes TYK2, JAK1, JAK2, and JAK3, with IC50 values of 4.2 nM, 32Formula:C17H19F2N7OSPurity:98%Color and Shape:SolidMolecular weight:407.44QL-1200186
CAS:QL-1200186 is an orally active, selective TYK2 inhibitor that, upon dose-dependent oral administration, suppresses interferon-γ (IFNγ) production followingFormula:C26H27N7O3Purity:98%Color and Shape:SolidMolecular weight:485.54JAK-IN-5
CAS:JAK-IN-5 is a JAK inhibitor.Formula:C27H31FN6OPurity:98.1% - 99.37%Color and Shape:SolidMolecular weight:474.57Ref: TM-T11710
1mg177.00€5mg370.00€10mg552.00€25mg879.00€50mg1,189.00€100mg1,603.00€500mg3,205.00€1mL*10mM (DMSO)537.00€Brepocitinib
CAS:Brepocitinib (PF-06700841) is a potent dual JAK1/TYK2 inhibitor (IC50s: 17 nM/23 nM). Brepocitinib also inhibits JAK2/3 (IC50s: 77 nM/6.49 μM).Formula:C18H21F2N7OPurity:99.82%Color and Shape:SolidMolecular weight:389.4Ref: TM-TQ0010
1mg34.00€2mg46.00€5mg66.00€10mg99.00€25mg205.00€50mg371.00€100mg595.00€200mg833.00€1mL*10mM (DMSO)73.00€
